To read the full story, subscribe or sign in.

Pharos Ibio wins MFDS orphan drug designation for AML drug

Sep. 5, 2024

South Korean artificial intelligence-based drug developer Pharos Ibio Co. Ltd. said that the Ministry of Food and Drug Safety (MFDS) granted an orphan drug designation for PHI-101, a second-line therapy for acute myeloid leukemia (AML).

BioWorld Regulatory American Society of Hematology Cancer Small molecule Asia-Pacific MOHW Orphan drug

Today's news in brief

BioWorld

BioWorld briefs for Aug. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 18, 2025.

Handshake with dollar sign and checkmark

Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal

BioWorld Science

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck...

Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal

BioWorld

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck...

Merck’s MK-2214 shows potential to slow Alzheimer’s pathology

BioWorld Science

Abnormal tau aggregation is a hallmark of Alzheimer’s disease (AD) and a major contributor to neurodegeneration, synaptic dysfunction, and progressive functional...